RHYTHM PHARMACEUTICALS, INC.
RYTMDrugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
4
Next Catalyst
Aug 4, 2026
26dMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
How RYTM's past catalysts played out
Class I or III Antiarrhythmic Medications
Atrial Fibrillation
Setmelanotide
Genetic Obesity
Flecainide or Sotalol or Propafenone
Paroxysmal Atrial Fibrillation
Setmelanotide 2 mg
Bardet-Biedl Syndrome
Part C: RM-718
Hypothalamic Obesity
LB54640
Hypothalamic Obesity
Diuretics
Heart Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Class I or III Antiarrhythmic Medications | Phase 3 | Atrial Fibrillation | - | - |
Setmelanotide | Phase 3 | Genetic Obesity | - | - |
Flecainide or Sotalol or Propafenone | Phase 3 | Paroxysmal Atrial Fibrillation | - | - |
Setmelanotide 2 mg | Phase 3 | Bardet-Biedl Syndrome | - | - |
Part C: RM-718 | Phase 2 | Hypothalamic Obesity | - | - |
LB54640 | Phase 2 | Hypothalamic Obesity | - | - |
Diuretics | Phase 2 | Heart Failure | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in RHYTHM PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in RHYTHM PHARMACEUTICALS, INC.'s (RYTM) pipeline across Phase 3, Phase 2. Its lead program is Class I or III Antiarrhythmic Medications (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RHYTHM PHARMACEUTICALS, INC.'s next FDA catalyst?→
RHYTHM PHARMACEUTICALS, INC.'s (RYTM) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RYTM biotech catalysts?→
Add RYTM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RHYTHM PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.